Aytu BioPharma (NASDAQ:AYTU) Raised to Hold at Wall Street Zen

Aytu BioPharma (NASDAQ:AYTU) was upgraded by Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Friday, January 9th. Ascendiant Capital Markets increased their price objective on Aytu BioPharma from $12.50 to $13.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Finally, Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Aytu BioPharma has a consensus rating of “Hold” and an average price target of $9.33.

Aytu BioPharma Stock Up 3.9%

Aytu BioPharma stock opened at $2.39 on Friday. The stock has a market capitalization of $25.64 million, a PE ratio of -0.62 and a beta of 0.37. Aytu BioPharma has a twelve month low of $0.95 and a twelve month high of $3.07. The company has a quick ratio of 1.08, a current ratio of 1.16 and a debt-to-equity ratio of 0.70. The company has a 50 day moving average of $2.52 and a 200-day moving average of $2.34.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.79). The company had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million. Aytu BioPharma had a negative return on equity of 28.22% and a negative net margin of 39.02%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in AYTU. Daytona Street Capital LLC bought a new stake in shares of Aytu BioPharma during the 4th quarter worth approximately $26,000. Bellevue Asset Management LLC bought a new stake in Aytu BioPharma during the fourth quarter worth $65,000. Dimensional Fund Advisors LP acquired a new stake in Aytu BioPharma in the third quarter valued at $58,000. FNY Investment Advisers LLC lifted its stake in Aytu BioPharma by 24,207.7% in the fourth quarter. FNY Investment Advisers LLC now owns 31,600 shares of the company’s stock valued at $82,000 after acquiring an additional 31,470 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Aytu BioPharma by 96.2% in the 3rd quarter. Two Sigma Investments LP now owns 68,736 shares of the company’s stock valued at $129,000 after acquiring an additional 33,701 shares during the period. Institutional investors and hedge funds own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.